Adjuvant therapy with high-dose interferon α2b in patients with high-risk stage IIB/III melanoma

In 2007, a predictably curative therapy for metastatic melanoma has yet to be identified, but we have begun to understand the immunosuppressive impact of melanoma upon the human host, and how melanoma evades the immune response through the induction of tumor tolerance.1 Interferon α2b (IFN-α2b) at high dosage is critical to the reversal of signaling defects… CONTINUE READING